Fruzaqla (FRUQUINTINIB)
Fruzaqla (FRUQUINTINIB) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Fruzaqla; Generic name: FRUQUINTINIB; Manufacturer: Takeda Pharmaceuticals America, Inc..
| Brand name | Fruzaqla |
|---|---|
| Generic name | FRUQUINTINIB |
| Manufacturer | Takeda Pharmaceuticals America, Inc. |
| Used for | 1. INDICATIONS AND USAGE FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. ( 1 ) |
| Dosage | 2. DOSAGE AND ADMINISTRATION The recommended dose of FRUZAQLA is 5 mg orally once daily, with or without food for the first 21 days of each 28-day cycle. ( 2.1 ) 2.1. Recommended Dosage The recommended dose of FRUZAQLA is 5 mg orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take FRUZAQLA with or without food [see Clinical Pharmacology (12.3) ] at approximately the same time each day. Swallow the FRUZAQLA capsule whole. Take a misse |
| Active ingredient(s) | FRUQUINTINIB |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=186d786e-dc8a-45f2-b5e1-01ac0201879f |